0000000000496081
AUTHOR
Juan Francisco Merino Torres
Terminology and classification of miracle slimming diets: A narrative review and new proposals
Introduction: In the last years, confusing or misleading use of the term called miracle or magic diets, using to weight loss treatment, has increased, along with several classification of them. Objectives: The purpose of this narrative review is to discuss miracle slimming diets and proposal new term and new classification for these diets. Methods: A narrative review up to September 2021 was carried out in the PubMed, Google Scholar, and Web of Knowledge. Furthermore, this strategy was complemented with a comprehensive search of the 'grey' literature [7] based in four different searching strategies: i) grey literature databases, ii) customized Google search engines, iii) targeted websites, …
Development, validation and implementation of a program to detect malnutrition with NRS-2002 screening tool in patients from the oncology and hematology service
Introduction: Hospital malnutrition (HM) is an increasingly prevalent situation, which involves both an increase in health costs, and also a decrease in the life quality and greater morbimortality. Nutritional screening is essential to detect malnutrition early and avoid these complications. Objectives: To develop, validate and implement the Nutritional Risk Screening 2002 (NRS-2002) tool at the admission and during the hospitalization of a patient in the oncohematology service in a third level hospital, and know their nutritional status at the admission and the discharge. Methods: NRS-2002 was performed on all patients admitted to the oncohaematology service, followed by the complete nutri…
Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
Ajuda rebuda: GlaxoSmithKline Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics.Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment …
GLP 1 receptor agonists, glycemic variability, oxidative stress and acute coronary syndrome
Abstract Glycemic variability (GV) has been recently described as an independent cardiovascular risk factor in patients with acute coronary syndrome (ACS). Also, new findings suggest that GV plays an important role in the development of complications related to impaired glucose metabolism and oxidative stress. On the other hand, although treatment for diabetes can reduce HbA1c in a similar extent their effectiveness over GV can be radically different. Patients in the acute setting of a coronary syndrome should be strictly monitorized to maintain glucose within recommended values; avoiding values lower than 90 mg/dL (5 mmol/L) and higher than 180 mg/dL (10 mmol/L). Also, evidence suggests th…
“Five Keys to Safer Food” and COVID-19
On 11 March 2020, coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO) and, up to 18:37 a.m. on 9 December 2021, it has produced 268,440,530 cases and 5,299,511 deaths. This disease, in some patients, included pneumonia and shortness of breath, being transmitted through droplets and aerosols. To date, there is no scientific literature to justify transmission directly from foods. In this review, we applied the precautionary principle for the home and the food industry using the known “Five Keys to Safer Food” manual developed by the World Health Organization (WHO) and extended punctually in its core information from five keys, in the light of new…
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Background Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable insulin in patients with inadequately controlled type 1 diabetes. Methods DEPICT-1 was a double-blind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17 countries. Eligible patients were aged 18–75 years and had inadequately controlled type 1 diabetes (HbA1c between ≥7·7% and ≤11·0% [≥61·0 mmol/mol and ≤97·0 mmol/mol]) and had been prescribed insulin for at least 12 months before enrolment. After an 8 week lead-in period to optimise diabetes man…